Long Beach, United States
Dermavant Sciences, an Organon company, operates within the Biotechnology and Health Care industries. Founded in 2016 and headquartered in the United States, Dermavant has carved a niche in the specialty biopharmaceutical sector by focusing on cutting-edge therapies for dermatologic diseases.
The company's tagline, "A Passion for Science and a Commitment to Dermatology," encapsulates its mission. Dermavant's strategy involves acquiring promising compounds to address unmet therapeutic needs, rapidly building a robust dermatology R&D pipeline. Their commitment lies in developing and commercializing novel first-in-class or best-in-class therapies aimed at enhancing patients' lives.
In its latest financial move, Dermavant raised $160.00M in a Private Equity Round on 07 June 2021, backed by significant investors like Marathon Fund and Novaquest Capital Management. Dermavant represents an attractive prospect for investors seeking innovation-driven growth in dermatological biopharmaceutical solutions.
